CANF — Can Fite Biopharma Share Price
Last trade - 00:00- $15.71m
- $10.98m
- $0.74m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.34 | ||
| Price to Tang. Book | 6.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 23.56 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -198.04% | ||
| Return on Equity | -157.62% | ||
| Operating Margin | -1168.37% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.03 | 0.76 | 0.85 | 0.81 | 0.74 | 0.6 | 13.52 | -27.92% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Directors
- Ilan Cohen CHM (64)
- Pnina Fishman CEO (70)
- Motti Farbstein CFO (51)
- Golan Bitton DRC (43)
- Guy Regev DRC (48)
- Abraham Sartani DRC (68)
- Israel Shamay DRC (51)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- September 11th, 1994
- Public Since
- September 22nd, 2005
- No. of Employees
- 5
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 2,983,181,793
- Address
- 26 Ben Gurion Street, RAMAT GAN, 5257346
- Web
- https://www.canfite.com/
- Phone
- +972 39241114
- Auditors
- Kost, Forer, Gabbay & Kasierer
Upcoming Events for CANF
Similar to CANF
cbdMD
NYSE MKT
CEL-SCI
NYSE MKT
China Pharma Holdings
NYSE MKT
NovaBay Pharmaceuticals
NYSE MKT
Protalix Biotherapeutics
NYSE MKT
FAQ
As of Today at 18:46 UTC, shares in Can Fite Biopharma are trading at $1.58. This share price information is delayed by 15 minutes.
Shares in Can Fite Biopharma last closed at $1.58 and the price had moved by -21.78% over the past 365 days. In terms of relative price strength the Can Fite Biopharma share price has underperformed the S&P500 Index by -35.79% over the past year.
The overall consensus recommendation for Can Fite Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCan Fite Biopharma does not currently pay a dividend.
Can Fite Biopharma does not currently pay a dividend.
Can Fite Biopharma does not currently pay a dividend.
To buy shares in Can Fite Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.58, shares in Can Fite Biopharma had a market capitalisation of $15.71m.
Here are the trading details for Can Fite Biopharma:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: CANF
Based on an overall assessment of its quality, value and momentum Can Fite Biopharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Can Fite Biopharma is $13.26. That is 739.01% above the last closing price of $1.58.
Analysts covering Can Fite Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$1.37 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Can Fite Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -56%.
As of the last closing price of $1.58, shares in Can Fite Biopharma were trading -32.32% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Can Fite Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Can Fite Biopharma's management team is headed by:
- Ilan Cohen - CHM
- Pnina Fishman - CEO
- Motti Farbstein - CFO
- Golan Bitton - DRC
- Guy Regev - DRC
- Abraham Sartani - DRC
- Israel Shamay - DRC